Ultragenyx beefs up its take in $186M offering; Idera raises $75M;

@FierceBiotech: Low-profile biotech gets $30M, new CEO and new home for PhIII atrial fib effort. Report | Follow @FierceBiotech

@JohnCFierce: ICYMI: AstraZeneca struggles to spin out anti-infectives division, coming down to the wire. Editor's corner | Follow @JohnCFierce

@DamianFierce: Sprout is resubmitting its "female Viagra" as the FDA faces pressure from advocacy groups. Release | Follow @DamianFierce

> Ultragenyx ($RARE) sold an additional 450,000 shares at $54 a share to the underwriters of its announced offering. The biotech grossed $186 million in the offering. Release

> Idera Pharmaceuticals ($IDRA) raised $75 million in a follow-on offering. Release

Medical Device News

@FierceMedDev: ICYMI: ACT Genomics ropes in $8M for cancer molecular Dx in first private funding round. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: Quick, low-cost tests are becoming the new norm in screening for infectious diseases. Report from the WSJ | Follow @EmilyWFierce

> Hospitals purchasing MRI, CT scanners to take real-time images during surgery. More

> Israeli seed device firm Rainbow Medical raises $25M from Chinese investors. Report

> Swiss developers debut telescopic contact lens triggered by blinking. Story

> Kleiner Perkins-backed Invuity hauls in $20M for surgical lighting tools. Article

Pharma News

@FiercePharma: Aratana confirms hold on USDA-approved dog lymphoma drug. FierceAnimalHealth story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Activists ready to fight for Ariad CEO's ouster: CNBC. Article | Follow @CarlyHFierce

> Shanghai official linked to GSK bribery sentenced to 19 years in prison. News

> Glaxo's Connelly bows out amid scramble to turn around U.S. business. Article

> Le Figaro: Sanofi will tap Bayer's Brandicourt as CEO this week. Report

Biotech IT News

> Medidata's wearables wish list: Long battery life and water resistance. More

> Microsoft, Cambridge University team up on blood cancer simulation model. Story

> RainDance Technologies opens patent suit against 10X Genomics. Item

> Sanofi-backed virtual trial gets green light in Europe. Report

> Ex-J&J exec turns to crowd to fund brain disorder simulation project. Article

CRO News

> Actavis sells its outsourcing biz to TPG. Item

> Catalent's string of deals pads its pocketbook. More

> Quintiles looks to 2015 with another banner year in the books. Story

> AMRI posts a net quarterly loss in the midst of a realignment. Article

> Charles River rides M&A to a big revenue year. Report

Animal Health News

> Aratana confirms hold on USDA-approved dog lymphoma drug. Item

> Phibro climbs on strong revenue growth, high hopes for new vaccine venture. More

> Trupanion doubles down on quest to make pet insurance more palatable. Story

> Veterinary trade group denounces press reports of alleged conflicts of interest. Article

> Embattled Zoetis beats Q4 expectations, but tempers 2015 forecasts. Report

Biotech Research News

> Singapore research team develops new strategy on inflammation cancer targeting. More

> Science team spotlights a potentially game-changing approach for ovarian cancer. Story

> Investigators advance a new therapy to use against pneumonia, influenza. Article

> Stem cell work points to new approach on fighting obesity. Item

> Alzheimer's group spawns three new R&D centers to advance promising therapies. Report

Pharma Manufacturing News

> Samsung BioLogics to expand new biologics plant. News

> Sun Pharma's revenues squeezed by plant issues. More

> Claris' injectables business is said to be shopped to Pfizer, Amneal. Story

> TPG buys back Aptalis' Pharmatech unit from Actavis. Article

> AMRI plans to close plant in Wales. Report

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.